LEXICON PHARMACEUTICALS, INC. Net Income
LEXICON PHARMACEUTICALS, INC. (LXRX) reported Net Income of -$31.77 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:NetIncomeLoss · last filed 2026-08-06
- LEXICON PHARMACEUTICALS, INC. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$31.77M, a 1077.09% decline year-over-year.
- LEXICON PHARMACEUTICALS, INC. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$1.04M.
- LEXICON PHARMACEUTICALS, INC. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$15.53M.
- LEXICON PHARMACEUTICALS, INC. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$12.77M.
- LEXICON PHARMACEUTICALS, INC. net income (loss) attributable to parent for fiscal 2025 was -$50.34M.
- LEXICON PHARMACEUTICALS, INC. net income (loss) attributable to parent for fiscal 2024 was -$200.40M.
- LEXICON PHARMACEUTICALS, INC. net income (loss) attributable to parent for fiscal 2023 was -$177.12M.
- LEXICON PHARMACEUTICALS, INC. net income (loss) attributable to parent for fiscal 2022 was -$101.94M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 3 month as first filed | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 6 month as first filed | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 9 month as first filed | Net Income (Loss) Attributable to Parent 12 month | Net Income (Loss) Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$31.77M 10-Q · filed 2026-08-06 | -$32.82M 10-Q · filed 2026-08-06 | -$48.35M derived: sum of 3 quarters · filed 2026-08-06 | -$61.12M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | -$1.04M 10-Q · filed 2026-08-06 | -$16.57M derived: sum of 2 quarters · filed 2026-08-06 | -$29.34M derived: sum of 3 quarters · filed 2026-08-06 | -$26.09M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | -$15.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$28.30M derived: sum of 2 quarters · filed 2026-03-05 | -$25.05M derived: sum of 3 quarters · filed 2026-08-06 | -$50.34M 10-K · filed 2026-03-05 | ||||
| 2025-09-30 | -$12.77M 10-Q · filed 2025-11-06 | -$9.52M derived: sum of 2 quarters · filed 2026-08-06 | -$34.81M 10-Q · filed 2025-11-06 | -$68.58M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $3.25M 10-Q · filed 2026-08-06 | -$22.04M 10-Q · filed 2026-08-06 | -$55.81M derived: sum of 3 quarters · filed 2026-08-06 | -$120.62M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | -$25.30M 10-Q · filed 2026-08-06 | -$59.06M derived: sum of 2 quarters · filed 2026-08-06 | -$123.87M derived: sum of 3 quarters · filed 2026-08-06 | -$177.30M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2024-12-31 | -$33.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$98.58M derived: sum of 2 quarters · filed 2026-03-05 | -$152.01M derived: sum of 3 quarters · filed 2026-03-05 | -$200.40M 10-K · filed 2026-03-05 | ||||
| 2024-09-30 | -$64.81M 10-Q · filed 2025-11-06 | -$118.24M derived: sum of 2 quarters · filed 2025-11-06 | -$166.64M 10-Q · filed 2025-11-06 | -$216.39M derived: sum of 4 quarters · filed 2026-03-05 | ||||
| 2024-06-30 | -$53.43M 10-Q · filed 2025-11-06 | -$101.83M 10-Q · filed 2025-08-06 | -$151.58M derived: sum of 3 quarters · filed 2026-03-05 | -$202.11M derived: sum of 4 quarters · filed 2026-03-05 | ||||
| 2024-03-31 | -$48.40M 10-Q · filed 2025-11-06 | -$98.15M derived: sum of 2 quarters · filed 2026-03-05 | -$148.68M derived: sum of 3 quarters · filed 2026-03-05 | -$193.58M derived: sum of 4 quarters · filed 2026-03-05 | ||||
| 2023-12-31 | -$49.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$100.28M derived: sum of 2 quarters · filed 2026-03-05 | -$145.19M derived: sum of 3 quarters · filed 2026-03-05 | -$177.12M 10-K · filed 2026-03-05 | ||||
| 2023-09-30 | -$50.52M 10-Q · filed 2024-11-13 | -$95.43M derived: sum of 2 quarters · filed 2024-11-13 | -$127.36M 10-Q · filed 2024-11-13 | -$157.86M derived: sum of 4 quarters · filed 2025-03-07 | ||||
| 2023-06-30 | -$44.90M 10-Q · filed 2024-11-13 | -$76.84M 10-Q · filed 2024-08-02 | -$107.33M derived: sum of 3 quarters · filed 2025-03-07 | -$130.72M derived: sum of 4 quarters · filed 2025-03-07 | ||||
| 2023-03-31 | -$31.93M 10-Q · filed 2024-11-13 | -$62.43M derived: sum of 2 quarters · filed 2025-03-07 | -$85.81M derived: sum of 3 quarters · filed 2025-03-07 | -$110.40M derived: sum of 4 quarters · filed 2025-03-07 | ||||
| 2022-12-31 | -$30.49M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | -$53.88M derived: sum of 2 quarters · filed 2025-03-07 | -$78.47M derived: sum of 3 quarters · filed 2025-03-07 | -$101.94M 10-K · filed 2025-03-07 | ||||
| 2022-09-30 | -$23.39M 10-Q · filed 2023-11-08 | -$47.97M derived: sum of 2 quarters · filed 2023-11-08 | -$71.45M 10-Q · filed 2023-11-08 | -$97.06M derived: sum of 4 quarters · filed 2024-03-25 | ||||
| 2022-06-30 | -$24.59M 10-Q · filed 2023-11-08 | -$48.06M 10-Q · filed 2023-08-04 | -$73.67M derived: sum of 3 quarters · filed 2024-03-25 | -$96.80M derived: sum of 4 quarters · filed 2024-03-25 | ||||
| 2022-03-31 | -$23.48M 10-Q · filed 2023-11-08 | -$49.09M derived: sum of 2 quarters · filed 2024-03-25 | -$72.21M derived: sum of 3 quarters · filed 2024-03-25 | -$90.28M derived: sum of 4 quarters · filed 2024-03-25 | ||||
| 2021-12-31 | -$25.61M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | -$48.73M derived: sum of 2 quarters · filed 2024-03-25 | -$66.80M derived: sum of 3 quarters · filed 2024-03-25 | -$87.76M 10-K · filed 2024-03-25 | ||||
| 2021-09-30 | -$23.12M 10-Q · filed 2022-11-09 | -$41.19M derived: sum of 2 quarters · filed 2022-11-09 | -$62.15M 10-Q · filed 2022-11-09 | -$67.64M derived: sum of 4 quarters · filed 2023-03-03 | ||||
| 2021-06-30 | -$18.07M 10-Q · filed 2022-08-03 | -$39.02M 10-Q · filed 2022-08-03 | -$44.52M derived: sum of 3 quarters · filed 2023-03-03 | $38.08M derived: sum of 4 quarters · filed 2023-03-03 | ||||
| 2021-03-31 | -$20.96M 10-Q · filed 2022-05-05 | -$26.45M derived: sum of 2 quarters · filed 2023-03-03 | $56.15M derived: sum of 3 quarters · filed 2023-03-03 | -$12.92M derived: sum of 4 quarters · filed 2023-03-03 | ||||
| 2020-12-31 | -$5.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | $77.11M derived: sum of 2 quarters · filed 2023-03-03 | $8.04M derived: sum of 3 quarters · filed 2023-03-03 | -$58.57M 10-K · filed 2023-03-03 | ||||
| 2020-09-30 | $82.60M 10-Q · filed 2021-11-09 | $13.53M derived: sum of 2 quarters · filed 2021-11-09 | -$53.08M 10-Q · filed 2021-11-09 | -$104.22M derived: sum of 4 quarters · filed 2021-11-09 | ||||
| 2020-06-30 | -$69.07M 10-Q · filed 2021-08-06 | -$135.68M 10-Q · filed 2021-08-06 | -$186.82M derived: sum of 3 quarters · filed 2021-08-06 | $39.27M derived: sum of 4 quarters · filed 2021-08-06 | ||||
| 2020-03-31 | -$66.61M 10-Q · filed 2021-05-06 | -$117.75M derived: sum of 2 quarters · filed 2021-05-06 | $108.34M derived: sum of 3 quarters · filed 2021-05-06 | $85.32M derived: sum of 4 quarters · filed 2021-05-06 | ||||
| 2019-12-31 | -$51.14M 10-K · filed 2020-03-12 | $174.95M derived: sum of 2 quarters · filed 2020-10-30 | $151.93M derived: sum of 3 quarters · filed 2020-10-30 | $130.13M 10-K · filed 2022-03-10 | ||||
| 2019-09-30 | $226.09M 10-Q · filed 2020-10-30 | $203.07M derived: sum of 2 quarters · filed 2020-10-30 | $181.27M 10-Q · filed 2020-10-30 | $164.49M derived: sum of 4 quarters · filed 2020-10-30 | ||||
| 2019-06-30 | -$23.02M 10-Q · filed 2020-07-29 | -$44.81M 10-Q · filed 2020-07-29 | -$61.60M derived: sum of 3 quarters · filed 2020-07-29 | -$88.99M derived: sum of 4 quarters · filed 2020-07-29 | ||||
| 2019-03-31 | -$21.80M 10-Q · filed 2020-04-27 | -$38.58M derived: sum of 2 quarters · filed 2020-04-27 | -$65.97M derived: sum of 3 quarters · filed 2020-04-27 | -$100.52M derived: sum of 4 quarters · filed 2020-04-27 | ||||
| 2018-12-31 | -$16.78M 10-K · filed 2020-03-12 | -$16.78M 10-K · filed 2019-03-15 | -$44.18M derived: sum of 2 quarters · filed 2020-03-12 | -$78.73M derived: sum of 3 quarters · filed 2020-03-12 | -$120.55M 10-K · filed 2021-03-12 | |||
| 2018-09-30 | -$27.40M 10-K · filed 2020-03-12 | -$27.51M 10-Q · filed 2018-11-01 | -$61.95M derived: sum of 2 quarters · filed 2020-03-12 | -$103.77M 10-Q · filed 2019-11-07 | -$104.29M 10-Q · filed 2018-11-01 | -$130.38M derived: sum of 4 quarters · filed 2020-03-12 | ||
| 2018-06-30 | -$34.55M 10-K · filed 2020-03-12 | -$34.71M 10-Q · filed 2018-07-30 | -$76.37M 10-Q · filed 2019-08-01 | -$76.78M 10-Q · filed 2018-07-30 | -$102.98M derived: sum of 3 quarters · filed 2020-03-12 | -$132.79M derived: sum of 4 quarters · filed 2020-03-12 | ||
| 2018-03-31 | -$41.82M 10-K · filed 2020-03-12 | -$42.08M 10-Q · filed 2018-05-03 | -$68.43M derived: sum of 2 quarters · filed 2020-03-12 | -$98.24M derived: sum of 3 quarters · filed 2020-03-12 | -$132.90M derived: sum of 4 quarters · filed 2020-03-12 | |||
| 2017-12-31 | -$26.61M 10-K · filed 2019-03-15 | -$28.38M 10-K · filed 2018-03-01 | -$56.42M derived: sum of 2 quarters · filed 2019-03-15 | -$91.08M derived: sum of 3 quarters · filed 2019-03-15 | -$122.99M 10-K · filed 2020-03-12 | -$129.05M 10-K · filed 2018-03-01 | ||
| 2017-09-30 | -$29.81M 10-K · filed 2019-03-15 | -$30.72M 10-Q · filed 2017-11-08 | -$64.47M derived: sum of 2 quarters · filed 2019-03-15 | -$100.67M 10-Q · filed 2018-11-01 | -$128.80M derived: sum of 4 quarters · filed 2019-03-15 | |||
| 2017-06-30 | -$34.66M 10-K · filed 2019-03-15 | -$35.06M 10-Q · filed 2017-08-01 | -$69.95M 10-Q · filed 2018-07-30 | -$98.99M derived: sum of 3 quarters · filed 2019-03-15 | -$135.01M derived: sum of 4 quarters · filed 2019-03-15 | |||
| 2017-03-31 | -$31.92M 10-K · filed 2019-03-15 | -$34.89M 10-Q · filed 2017-05-04 | -$64.34M derived: sum of 2 quarters · filed 2019-03-15 | -$100.35M derived: sum of 3 quarters · filed 2019-03-15 | -$138.46M derived: sum of 4 quarters · filed 2019-03-15 | |||
| 2016-12-31 | -$32.42M 10-K · filed 2018-03-01 | -$68.43M derived: sum of 2 quarters · filed 2018-03-01 | -$106.55M derived: sum of 3 quarters · filed 2018-03-01 | -$131.44M 10-K · filed 2019-03-15 | -$141.43M 10-K · filed 2017-03-06 | |||
| 2016-09-30 | -$36.02M 10-K · filed 2018-03-01 | -$74.13M derived: sum of 2 quarters · filed 2018-03-01 | -$109.01M 10-Q · filed 2017-11-08 | -$22.26M derived: sum of 4 quarters · filed 2018-03-01 | ||||
| 2016-06-30 | -$38.11M 10-K · filed 2018-03-01 | -$73.00M 10-Q · filed 2017-08-01 | $13.76M derived: sum of 3 quarters · filed 2018-03-01 | -$21.53M derived: sum of 4 quarters · filed 2018-03-01 | ||||
| 2016-03-31 | -$34.88M 10-K · filed 2018-03-01 | $51.87M derived: sum of 2 quarters · filed 2018-03-01 | $16.59M derived: sum of 3 quarters · filed 2018-03-01 | -$11.49M derived: sum of 4 quarters · filed 2018-03-01 | ||||
| 2015-12-31 | $86.75M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $51.47M derived: sum of 2 quarters · filed 2018-03-01 | $23.39M derived: sum of 3 quarters · filed 2018-03-01 | -$4.68M 10-K · filed 2018-03-01 | ||||
| 2015-09-30 | -$35.28M 10-Q · filed 2016-11-07 | -$63.36M derived: sum of 2 quarters · filed 2016-11-07 | -$91.43M 10-Q · filed 2016-11-07 | -$94.36M derived: sum of 4 quarters · filed 2016-11-07 | ||||
| 2015-06-30 | -$28.07M 10-Q · filed 2016-08-04 | -$56.15M 10-Q · filed 2016-08-04 | -$59.08M derived: sum of 3 quarters · filed 2016-08-04 | -$99.58M derived: sum of 4 quarters · filed 2016-08-04 | ||||
| 2015-03-31 | -$28.08M 10-Q · filed 2016-05-05 | -$31.01M derived: sum of 2 quarters · filed 2016-05-05 | -$71.51M derived: sum of 3 quarters · filed 2016-05-05 | -$97.53M derived: sum of 4 quarters · filed 2016-05-05 | ||||
| 2014-12-31 | -$2.93M 10-K · filed 2015-03-12 | -$43.43M derived: sum of 2 quarters · filed 2015-11-09 | -$69.46M derived: sum of 3 quarters · filed 2015-11-09 | -$100.29M 10-K · filed 2017-03-06 | ||||
| 2014-09-30 | -$40.50M 10-Q · filed 2015-11-09 | -$66.53M derived: sum of 2 quarters · filed 2015-11-09 | -$97.36M 10-Q · filed 2015-11-09 | -$114.78M derived: sum of 4 quarters · filed 2015-11-09 | ||||
| 2014-06-30 | -$26.03M 10-Q · filed 2015-08-07 | -$56.86M 10-Q · filed 2015-08-07 | -$74.28M derived: sum of 3 quarters · filed 2015-08-07 | -$105.94M derived: sum of 4 quarters · filed 2015-08-07 | ||||
| 2014-03-31 | -$30.84M 10-Q · filed 2015-05-05 | -$48.25M derived: sum of 2 quarters · filed 2015-05-05 | -$79.91M derived: sum of 3 quarters · filed 2015-05-05 | -$108.99M derived: sum of 4 quarters · filed 2015-05-05 | ||||
| 2013-12-31 | -$17.41M 10-K · filed 2015-03-12 | -$49.07M derived: sum of 2 quarters · filed 2015-03-12 | -$78.15M derived: sum of 3 quarters · filed 2015-03-12 | -$104.13M 10-K · filed 2016-03-11 | ||||
| 2013-09-30 | -$31.66M 10-K · filed 2015-03-12 | -$60.74M derived: sum of 2 quarters · filed 2015-03-12 | -$86.71M 10-Q · filed 2014-11-06 | -$111.58M derived: sum of 4 quarters · filed 2015-03-12 | ||||
| 2013-06-30 | -$29.08M 10-K · filed 2015-03-12 | -$55.05M 10-Q · filed 2014-08-07 | -$79.93M derived: sum of 3 quarters · filed 2015-03-12 | -$109.47M derived: sum of 4 quarters · filed 2015-03-12 | ||||
| 2013-03-31 | -$25.97M 10-K · filed 2015-03-12 | -$50.85M derived: sum of 2 quarters · filed 2015-03-12 | -$80.39M derived: sum of 3 quarters · filed 2015-03-12 | -$106.32M derived: sum of 4 quarters · filed 2015-03-12 | ||||
| 2012-12-31 | -$24.87M 10-K · filed 2014-03-07 | -$54.41M derived: sum of 2 quarters · filed 2014-03-07 | -$80.34M derived: sum of 3 quarters · filed 2014-03-07 | -$110.21M 10-K · filed 2015-03-12 | ||||
| 2012-09-30 | -$29.54M 10-K · filed 2014-03-07 | -$55.47M derived: sum of 2 quarters · filed 2014-03-07 | -$85.34M 10-Q · filed 2013-11-12 | -$119.18M derived: sum of 4 quarters · filed 2014-03-07 | ||||
| 2012-06-30 | -$25.93M 10-K · filed 2014-03-07 | -$55.80M 10-Q · filed 2013-08-01 | -$89.64M derived: sum of 3 quarters · filed 2014-03-07 | -$115.75M derived: sum of 4 quarters · filed 2014-03-07 | ||||
| 2012-03-31 | -$29.87M 10-K · filed 2014-03-07 | -$63.71M derived: sum of 2 quarters · filed 2014-03-07 | -$89.82M derived: sum of 3 quarters · filed 2014-03-07 | -$116.45M derived: sum of 4 quarters · filed 2014-03-07 | ||||
| 2011-12-31 | -$33.84M 10-K · filed 2013-03-11 | -$59.95M derived: sum of 2 quarters · filed 2013-03-11 | -$86.59M derived: sum of 3 quarters · filed 2013-03-11 | -$116.22M 10-K · filed 2014-03-07 | ||||
| 2011-09-30 | -$26.10M 10-K · filed 2013-03-11 | -$52.74M derived: sum of 2 quarters · filed 2013-03-11 | -$82.37M 10-Q · filed 2012-11-07 | -$105.37M derived: sum of 4 quarters · filed 2013-03-11 | ||||
| 2011-06-30 | -$26.64M 10-K · filed 2013-03-11 | -$56.27M 10-Q · filed 2012-08-02 | -$79.27M derived: sum of 3 quarters · filed 2013-03-11 | -$106.78M derived: sum of 4 quarters · filed 2013-03-11 | ||||
| 2011-03-31 | -$29.63M 10-K · filed 2013-03-11 | -$52.63M derived: sum of 2 quarters · filed 2013-03-11 | -$80.14M derived: sum of 3 quarters · filed 2013-03-11 | -$105.33M derived: sum of 4 quarters · filed 2013-03-11 | ||||
| 2010-12-31 | -$23.00M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-11 | -$50.51M derived: sum of 2 quarters · filed 2013-03-11 | -$75.70M derived: sum of 3 quarters · filed 2013-03-11 | -$101.78M 10-K · filed 2013-03-11 | ||||
| 2010-09-30 | -$27.51M 10-Q · filed 2011-11-01 | -$52.71M derived: sum of 2 quarters · filed 2011-11-01 | -$78.78M 10-Q · filed 2011-11-01 | |||||
| 2010-06-30 | -$25.19M 10-Q · filed 2011-08-09 | -$51.26M 10-Q · filed 2011-08-09 | ||||||
| 2009-12-31 | -$82.78M 10-K · filed 2012-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |